In pulmonary sarcomatoid carcinoma (PSC), a rare type of NSCLC, the mutation rate is as high as 31.8%.[8] As an independent indicator of poor prognosis, MET exon 14 skipping mutation is more common in elderly, man, and advanced NSCLC patients,[9–13] with various types and forms of mutation.[14] MET-TKIs (tyrosine kinase inhibitors), such as crizotinib, capmatinib, and tepotinib were proved effective treatment for NSCLC patients from clinical trials. Here, MET is linked to non-small cell lung carcinoma.